Combination of the ABL kinase inhibitor imatinib with the Janus kinase 2 inhibitor TG101348 for targeting residual BCR-ABL-positive cells
Crossref DOI link: https://0-doi-org.brum.beds.ac.uk/10.1186/1756-8722-7-37
Published Online: 2014-04-28
Published Print: 2014-12
Update policy: https://0-doi-org.brum.beds.ac.uk/10.1007/springer_crossmark_policy
Okabe, Seiichi
Tauchi, Tetsuzo
Katagiri, Seiichiro
Tanaka, Yuko
Ohyashiki, Kazuma
Article History
Received: 7 February 2014
Accepted: 22 April 2014
First Online: 28 April 2014